Back to news

Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer

Globe Newswire•18/11/2026•07:30 ET
1

Key Highlights

  • ➤Atebimetinib showed synergistic activity with KRAS G12C, G12D, and G12V inhibitors in preclinical PDAC models
  • ➤KRAS G12D combination activity was validated in an in vivo pancreatic cancer xenograft model
  • ➤Atebimetinib demonstrated synergy with PRMT5 inhibitors in MTAP-deleted tumor models
  • ➤MAPKeeper 301 is evaluating atebimetinib plus mGnP versus GnP in first-line pancreatic cancer
  • ➤Astellas collaboration will evaluate atebimetinib combinations with CLDN18.2-targeted agents in two trials

Expert Statements

Ben Zeskind, Co-founder and CEO of Immuneering

“We believe atebimetinib’s long survival, excellent tolerability profile, and broad all-comers activity reported in Phase 2 make it the increasingly likely backbone of choice for combinations with both chemotherapies and emerging agents that target subsets of pancreatic cancer patients”

Ben Zeskind, Co-founder and CEO of Immuneering

“Building on our recently announced collaboration targeting CLDN18.2-positive pancreatic cancer, these new findings demonstrate synergistic activity with multiple classes of emerging agents including PRMT5 inhibitors for tumors with MTAP deletions, as well as KRAS G12D and G12V inhibitors for tumors with those particular mutations.”

Ben Zeskind, Co-founder and CEO of Immuneering

“The data presented today strengthen the scientific rationale for developing atebimetinib as a backbone therapy in combination with additional agents targeting patient subsets in pancreatic cancer and suggest a broad set of potential opportunities to deploy atebimetinib in multiple combinations across multiple lines of therapy, starting with the exciting chemotherapy combination we are evaluating in our Phase 3 study, MAPKeeper 301.”

- Atebimetinib in combination with chemotherapies has shown excellent results in Phase 2, including long survival and an outstanding tolerability profile in an all-comers population of first-line pancreatic cancer patients treated with atebimetinib + mGnP, as presented in June at ASCO -

- Atebimetinib in combination with CLDN18.2-targeted agents will be evaluated in two clinical trials in recently announced collaboration with Astellas -

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in